Eisai (ESALY) stock price, revenue, and financials
Eisai market cap is $11.9 b, and annual revenue was ¥756.23 b in FY 2021
$42.58
$11.9 B
ESALY Mkt cap, 24-Jun-2022¥756.2 B
Eisai Revenue FY, 2021Eisai Gross profit (FY, 2021)634.4 B
Eisai Net income (FY, 2021)45.7 B
Eisai EBITDA (FY, 2021)92.1 B
Eisai EBIT (FY, 2021)53.7 B
Eisai Cash, 31-Mar-2022309.6 B
Eisai EV-202.8 B
Eisai Revenue Breakdown
Eisai revenue breakdown by business segment: 45.3% from PHARMACEUTICAL DIVERSIFIED, 9.4% from OTHER NONDISCLOSED and 45.3% from PHARMACEUTICAL DIVERSIFIED
Eisai revenue breakdown by geographic segment: 32.2% from Japan, 16.8% from Europe, 7.0% from Others, 30.0% from Americas and 14.1% from China
Eisai Income Statement
Annual
| JPY | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|
Revenue | 695.6b | 645.9b | 756.2b |
Cost of goods sold | (149.7b) | (133.8b) | (136.4b) |
Gross profit | 547.4b | 513.6b | 634.4b |
R&D expense | (140.1b) | (150.3b) | (171.7b) |
Operating expense total | (390.9b) | (424.0b) | (542.3b) |
Depreciation and amortization | (33.7b) | (36.3b) | (38.4b) |
EBITDA | 156.5b | 89.5b | 92.1b |
EBIT | 123.2b | 53.1b | 53.7b |
Interest expense | (1.1b) | (1.2b) | (1.7b) |
Interest income | 3.3b | 1.3b | 2.4b |
Pre tax profit | 128.1b | 52.6b | 54.5b |
Income tax expense | (5.6b) | (10.1b) | (8.7b) |
Net Income | 122.5b | 42.5b | 45.7b |
EPS | 424.8 | 146.9 | 167.3 |
Quarterly
| JPY | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 154.0b | 145.3b | 186.8b | 165.6b | 151.5b | 181.3b | 198.9b | 163.5b | 203.0b |
Cost of goods sold | (34.6b) | (34.9b) | (32.6b) | (29.6b) | (32.4b) | (31.3b) | (29.8b) | (32.4b) | (32.7b) |
Gross profit | 124.2b | 111.0b | 155.3b | 136.7b | 118.9b | 150.2b | 182.5b | 131.3b | 170.7b |
R&D expense | (29.4b) | (38.6b) | (35.0b) | (30.5b) | (37.0b) | (40.6b) | (41.8b) | (38.1b) | (43.4b) |
Operating expense total | (90.1b) | (99.3b) | (102.5b) | (95.9b) | (107.9b) | (117.4b) | (117.7b) | (117.6b) | (145.5b) |
Depreciation and amortization | (8.3b) | (5.4b) | (11.4b) | (8.7b) | (9.0b) | (9.2b) | (9.5b) | (8.2b) | (11.5b) |
EBITDA | 34.1b | 11.6b | 52.8b | 40.8b | 10.9b | 32.8b | 64.9b | 13.7b | 25.2b |
EBIT | 25.8b | 6.2b | 41.3b | 32.1b | 2.0b | 23.6b | 55.4b | 5.5b | 13.6b |
Interest expense | (304.0m) | (292.0m) | (311.0m) | (323.0m) | (304.0m) | (301.0m) | (374.0m) | (404.0m) | (405.0m) |
Interest income | 1.4b | 888.0m | 1.1b | 651.0m | 330.0m | 613.0m | 749.0m | 470.0m | 648.0m |
Pre tax profit | 27.0b | 6.8b | 42.1b | 32.4b | 2.0b | 23.9b | 55.8b | 5.6b | 13.9b |
Income tax expense | (4.9b) | (1.5b) | 4.5b | (7.7b) | (614.0m) | (4.2b) | (13.5b) | (1.3b) | (843.0m) |
Net Income | 22.1b | 5.3b | 46.5b | 24.8b | 1.4b | 19.7b | 42.3b | 4.2b | 13.0b |
EPS | 75.6 | 18.6 | 161.4 | 85.2 | 4.8 | 67.6 | 147.0 | 14.0 | 49.4 |
Eisai Balance Sheet
Annual
| JPY | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2022 |
|---|---|---|---|---|---|
Cash | 214.0b | 204.7b | 221.7b | 207.0b | 309.6b |
Accounts Receivable | 142.9b | 137.3b | 170.1b | 147.4b | 208.0b |
Inventories | 80.9b | 67.9b | 65.7b | 85.1b | 99.0b |
Current Assets | 535.9b | 561.7b | 521.4b | 518.3b | 640.6b |
PP&E | 103.1b | 105.2b | 144.6b | 160.9b | 169.9b |
Goodwill | 165.0b | 172.2b | 168.7b | 171.8b | 191.8b |
Total Assets | 1.0t | 1.1t | 1.1t | 1.1t | 1.2t |
Accounts Payable | 36.4b | 31.3b | 31.0b | 28.3b | 108.1b |
Short-term debt | 16.4b | 49.0b | 35.0b | 40.0b | |
Current Liabilities | 241.7b | 295.7b | 252.0b | 256.0b | 313.3b |
Long-term debt | 156.7b | 89.9b | 54.9b | 49.9b | 94.9b |
Non-Current Liabilities | 193.3b | 123.8b | 107.5b | 106.1b | 154.4b |
Total Debt | 173.1b | 138.9b | 89.9b | 89.9b | 94.9b |
Total Liabilities | 434.9b | 419.5b | 359.5b | 362.1b | 467.8b |
Common Stock | 45.0b | 146.7b | 129.5b | 151.6b | 45.0b |
Additional Paid-in Capital | 77.6b | 77.6b | 77.6b | 77.6b | 77.6b |
Retained Earnings | 415.0b | 438.5b | 505.4b | 508.0b | 506.6b |
Total Equity | 614.1b | 652.0b | 702.6b | 727.9b | 771.5b |
Quarterly
| JPY | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 279.7b | 291.8b | 248.6b | 225.5b | 215.4b | 212.5b | 226.3b | 228.0b | 193.8b | 213.1b | 283.0b | 258.4b |
Accounts Receivable | 148.8b | 149.3b | 165.9b | 168.6b | 164.1b | 196.7b | 184.0b | 183.0b | 202.0b | 236.3b | 174.6b | 214.6b |
Inventories | 70.4b | 71.0b | 66.1b | 63.9b | 65.1b | 66.4b | 70.9b | 74.9b | 78.9b | 89.9b | 90.0b | 92.5b |
Current Assets | 549.6b | 562.9b | 520.1b | 487.9b | 472.4b | 500.1b | 501.2b | 504.5b | 495.6b | 562.5b | 570.7b | 587.1b |
PP&E | 97.8b | 93.9b | 94.4b | 138.0b | 135.2b | 139.1b | 144.3b | 143.1b | 143.5b | 159.1b | 159.3b | 162.4b |
Goodwill | 171.5b | 176.1b | 172.1b | 167.1b | 167.3b | 169.9b | 167.0b | 164.1b | 160.6b | 171.6b | 173.7b | 178.6b |
Total Assets | 1.1t | 1.1t | 1.0t | 1.0t | 1.0t | 1.1t | 1.0t | 1.0t | 1.0t | 1.1t | 1.1t | 1.2t |
Accounts Payable | 52.6b | 52.1b | 51.4b | 58.3b | 52.9b | 60.3b | 61.9b | 77.9b | 70.2b | 80.8b | 76.3b | 90.6b |
Short-term debt | 29.0b | 40.0b | 40.0b | 40.0b | 60.5b | 59.0b | 35.0b | 42.8b | 40.0b | 40.0b | ||
Current Liabilities | 249.5b | 267.3b | 274.0b | 255.4b | 273.2b | 275.7b | 231.5b | 203.2b | 191.4b | 277.9b | 280.8b | 305.0b |
Long-term debt | 163.0b | 124.0b | 89.9b | 89.9b | 54.9b | 54.9b | 55.0b | 89.9b | 89.9b | 49.9b | 49.9b | 49.9b |
Non-Current Liabilities | 197.7b | 159.3b | 127.7b | 138.6b | 103.1b | 106.7b | 105.5b | 140.6b | 139.9b | 104.1b | 103.9b | 103.7b |
Total Debt | 192.0b | 163.9b | 129.9b | 129.9b | 115.4b | 113.9b | 89.9b | 89.9b | 89.9b | 92.7b | 89.9b | 89.9b |
Total Liabilities | 447.2b | 426.5b | 401.7b | 394.1b | 376.3b | 382.4b | 337.0b | 343.8b | 331.4b | 382.0b | 384.8b | 408.7b |
Common Stock | 145.6b | 157.0b | 144.1b | 130.2b | 126.4b | 139.7b | 127.4b | 125.2b | 123.1b | 152.9b | 155.5b | 170.1b |
Additional Paid-in Capital | 77.5b | 77.6b | 77.6b | 77.6b | 77.6b | 77.6b | 77.6b | 77.7b | 77.6b | 77.6b | 77.6b | 77.6b |
Retained Earnings | 407.1b | 429.5b | 412.9b | 434.8b | 440.2b | 461.8b | 508.0b | 509.6b | 505.6b | 526.0b | 531.2b | 521.1b |
Total Equity | 619.4b | 653.7b | 624.3b | 632.1b | 633.8b | 669.0b | 703.3b | 702.8b | 697.2b | 747.4b | 755.3b | 758.7b |
Eisai Cash Flow
Annual
| JPY | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2022 |
|---|---|---|---|---|---|
Net Income | 76.8b | 89.5b | 128.1b | 54.5b | |
Depreciation and Amortization | 26.2b | 26.8b | 33.7b | 38.4b | |
Cash From Operating Activities | 149.6b | 103.7b | 102.8b | 117.6b | |
Cash From Investing Activities | 17.0b | (7.9b) | (27.6b) | (28.8b) | |
Short-term Borrowings | 11.4b | (2.4b) | (9.0b) | ||
Long-term Borrowings | (50.0b) | (33.3b) | (48.9b) | (5.4b) | |
Dividends Paid | (42.9b) | (43.0b) | (45.8b) | (45.9b) | |
Cash From Financing Activities | (81.9b) | (79.2b) | (103.5b) | (49.0b) | |
Net Change in Cash | 83.8b | 21.4b | (37.7b) | 60.9b |
Quarterly
| JPY | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 21.3b | 49.7b | 59.5b | 27.0b | 33.8b | 75.8b | 32.4b | 34.4b | 58.4b | 55.8b | 61.3b | 75.2b |
Depreciation and Amortization | 6.9b | 13.7b | 20.1b | 8.3b | 16.5b | 25.1b | 8.7b | 17.7b | 26.8b | 9.5b | 19.3b | 29.2b |
Cash From Operating Activities | 12.3b | 49.9b | 60.5b | (4.1b) | 8.4b | 29.2b | 10.0b | 18.6b | 22.1b | (14.3b) | 68.4b | 73.2b |
Cash From Investing Activities | (1.6b) | (4.5b) | 3.0b | (20.1b) | (23.6b) | (26.5b) | (12.5b) | (17.4b) | (31.1b) | 124.0m | (8.0b) | (18.7b) |
Short-term Borrowings | 12.6b | (11.4b) | (11.4b) | (9.0b) | 16.5b | 15.0b | 2.8b | |||||
Long-term Borrowings | 5.0b | (19.0m) | (33.4b) | (2.3b) | (44.1b) | (46.7b) | (2.4b) | (5.2b) | (7.7b) | (2.5b) | (5.2b) | (7.8b) |
Dividends Paid | (22.9b) | (22.9b) | (43.0b) | (22.9b) | (22.9b) | (45.8b) | (22.9b) | (22.9b) | (45.9b) | (22.9b) | (22.9b) | (45.9b) |
Cash From Financing Activities | (5.4b) | (34.5b) | (88.1b) | (34.2b) | (50.5b) | (77.6b) | (25.4b) | (28.3b) | (53.6b) | (22.5b) | (27.9b) | (53.4b) |
Net Change in Cash | 9.2b | 21.3b | (21.9b) | (66.4b) | (76.5b) | (79.4b) | (27.9b) | (26.2b) | (60.5b) | (35.7b) | 34.3b | 9.7b |
Eisai Ratios
| JPY | FY, 2018 |
|---|
Eisai Operating Metrics
| Jul, 2018 | Jul, 2019 | Jul, 2020 | |
|---|---|---|---|
Phase I Trials Products | 15 | 14 | |
Phase II Trials Products | 13 | 15 | |
Phase I/II Trials Products | 6 | 6 | |
Phase III Trials Products | 11 | 14 | |
Phase II/III Trials Products | 1 | 1 | |
Filed Trials Products | 6 | 9 | |
Trials Products Approved | 9 | 8 | |
Products in Pipeline (Oncology) | 26 | 37 | 34 |
Phase I Trials Products (Oncology) | 10 | 11 | |
Phase II Trials Products (Oncology) | 8 | 9 | |
Phase I/II Trials Products (Oncology) | 5 | 6 | |
Phase III Trials Products (Oncology) | 3 | 10 | |
Filed Trials Products (Oncology) | 2 | ||
Trials Products Approved (Oncology) | 4 | 5 | |
Products in Pipeline (Neurology) | 15 | 13 | 9 |
Phase I Trials Products (Neurology) | 3 | 1 | |
Phase II Trials Products (Neurology) | 2 | 3 | |
Phase III Trials Products (Neurology) | 6 | 3 | |
Phase II/III Trials Products (Neurology) | 1 | 1 | |
Filed Trials Products (Neurology) | 3 | 9 | |
Trials Products Approved (Neurology) | 2 | 1 | |
Products in Pipeline (Gastrointestinal) | 7 | 4 | |
Phase I Trials Products (Gastrointestinal) | 1 | ||
Phase II Trials Products (Gastrointestinal) | 1 | 2 | |
Phase III Trials Products (Gastrointestinal) | 2 | 3 | |
Filed Trials Products (Gastrointestinal) | 1 | ||
Trials Products Approved (Gastrointestinal) | 3 | 1 |
